<DOC>
	<DOC>NCT00233883</DOC>
	<brief_summary>The purpose of this study is to evaluate the tolerability of a subcutaneous needle-free injection device used to administer Fuzeon, compared with the standard needle/syringe supplied with commercial Fuzeon. The anticipated time on study treatment is &lt;3 months, and the target sample size is &lt;100 individuals.</brief_summary>
	<brief_title>WAND Study - A Study to Evaluate Fuzeon (Enfuvirtide) Administered by a Needle-Free Injection Device in Patients With HIV.</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Enfuvirtide</mesh_term>
	<criteria>male or female patients, &gt;=18 years of age with HIV1 infection; previously treated with antiretroviral agents. prior use of Fuzeon or T1249; inability to selfinject; active, untreated opportunistic infection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>